We address today’s need for precision medicine

Symphogen is a private clinical late-stage antibody oncology focused biopharmaceutical company with a novel and differentiated antibody mixture pipeline and significant commercial opportunities.  Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations.

Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers.

We are headquartered in Denmark with operations in the US. At the end of 2017, we were 111 employees.

Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb products candidates. Our pipeline currently consists of eight clinical-stage programs of which four are proprietary and four are partnered.  We own the global development and commercialization rights to the product candidates Sym004, Sym013 and Sym015. Each of these product candidates has the potential to provide meaningful treatment options for cancer patients that are not currently available.

Our vision and strategy
We develop superior mAb therapeutics to improve the lives of patients with significant unmet medical needs.
Read more
DKK 787 million
Cash and cash equivalents and marketable securities at year-end 2017.
Read more
8 clinical programs
Clinical development of seven product candidates in eight different indications.
Read more

Our proprietary product candidates

A mixture of two mAbs inhibiting EGFR, Sym004 is being developed for the treatment of advanced meta­static colorectal cancer (mCRC) and for the treatment of advanced glioblastoma.

Possibly the first multi-targeting pan-HER antibody mixture consisting of six mAbs in one drug product, Sym013 is being developed for the treatment of advanced epithelial malignancies such as mCRC, pancreatic cancer, NSCLC and triple negative breast cancer.

A mixture of two mAbs, Sym015 is a potent MET inhibi­tor being developed for the treatment of MET amplified solid tumors.


mAb mixtures and cancer

Our science
We are pioneering the application of mAb mixtures as a differ­entiated approach to cancer therapy.
Read more
We seek partnerships with large biotechnology and pharmaceutical companies. Our current partners are Servier and Genentech.
Read more
Our values
Our values guide employees in their everyday work.
Read more
Read more about our proprietary and partnered clinical programs